Printer Friendly

WATSON PHARMACEUTICALS ANNOUNCES FDA APPROVAL FOR CARBIDOPA-LEVODOPA TABLET

 CORONA, Calif., Oct. 4 /PRNewswire/ -- Watson Pharmaceuticals (NASDAQ: WATS) today announced that its wholly owned subsidiary, Watson Laboratories Inc., has received approval from the Food and Drug Administration for an off-patent tablet form of Carbidopa-Levodopa. According to Allen Chao, president and chief executive officer, the Carbidopa-Levodopa tablet approval was for three dosage strengths; 10 mg.-100 mg.; 25 mg.-100 mg. and 25 mg.-250 mg. The Watson product will compete with Dupont Merck's Sinemet(R), a treatment for the symptoms of Parkinson's Disease. The total annual market size is estimated to be $100 million.
 Watson Pharmaceuticals manufactures and distributes off-patent pharmaceuticals and is developing advanced drug delivery systems designed to enhance the therapeutic benefits of pharmaceutical compounds.
 -0- 10/4/93
 /CONTACT: Doug Sherk, Ken Dennard, or Stuart Brunet, 415-296-7383, or June Filingeri or Miriam Adler, 212-850-5600, all of Morgen-Walke for Watson Pharmaceuticals/
 (WATS)


CO: Watson Pharmaceuticals ST: California IN: MTC SU:

TM-LH -- SF003 -- 8101 10/04/93 06:30 EDT
COPYRIGHT 1993 PR Newswire Association LLC
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 1993 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:PR Newswire
Date:Oct 4, 1993
Words:162
Previous Article:TRINET CORPORATE REALTY TRUST ACQUIRES MACFRUGAL'S BARGAINS -- CLOSE-OUT DISTRIBUTION FACILITY
Next Article:HEALTHCARE REFORM BINDER SERVICE ANNOUNCED BY FROST & SULLIVAN
Topics:

Terms of use | Copyright © 2017 Farlex, Inc. | Feedback | For webmasters